NEW YORK, Sept. 4 - French pharmaceutical company Sanofi-Synthelabo has become the latest subscriber to LifeSpan BioSciences' G protein-coupled receptor expression and location database, LifeSpan announced on Tuesday.
Sanofi will use LifeSpan’s database of GPCR expression and location information in normal and diseased tissues to help it identify and validate new drug targets.
Financial details of the agreement were not disclosed.
According to Michael Tippie, vice president of business development at LifeSpan, the company plans to use the licensing fees from Sanofi, along with some of the $19 million it raised in a private financing in April, to expand the number of GPCRs in the database to 320 from 160.
LifeSpan “can now guarantee to all subscribers” that the database will be expanded to the size it originally pledged, Tippie asserted.
LifeSpan’s database profiles GPCR expression in human diseases by integrating public DNA and protein sequence data with analysis of high-resolution digital photomicrograms of protein expression in normal and diseased tissues. Diseases could include the colon, breasts, lungs, kidneys, adrenal glands, mast cells, brain stem, skeletal muscle, and small intestine.
Sanofi-Synthelabo specializes in products for cardiovascular, CNS, and oncological disease. It is the fifth subscriber to the GPCR database, joining Pfizer, Merck, Bristol-Myers Squibb, and Novartis.
Since the cut-off date for adding new subscribers to the database of Dec. 21 is fast approaching, Tippie projected that LifeSpan may announce up to seven more agreements similar to Sanofi’s over the next few months.